Financings Of The Fortnight: Is Buoyant Biotech IPO Scene Altering Private Biotech M&A Trends?
This article was originally published in The Pink Sheet Daily
Executive Summary
When the IPO spigot runs dry, there’s M&A aplenty, and when the IPO wine is flowing, M&A slows down, right? FOTF tackles some conventional wisdom; plus deals from Acadia, Neurocrine, Aquinox, and Human Longevity.